<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996306</url>
  </required_header>
  <id_info>
    <org_study_id>AXEPT</org_study_id>
    <secondary_id>UMIN000012263</secondary_id>
    <nct_id>NCT01996306</nct_id>
  </id_info>
  <brief_title>A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC</brief_title>
  <acronym>AXEPT</acronym>
  <official_title>A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epidemiological and Clinical Research Information Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the non-inferiority of overall survival&#xD;
      XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as&#xD;
      Second-line therapy in Patient with Metastatic Colorectal Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: Overall survival (OS), Secondary endpoints: Progression-free survival&#xD;
      (PFS), Time to treatment failure (TTF), Overall response rate (ORR),Disease Control Rate&#xD;
      (DCR), Relative dose intensity, Safety, and Correlation between UGT1A1 genotype and Safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2013</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 20, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Assessed until 1.5 years after the last patient enrolment</time_frame>
    <description>Time from the date of enrollment to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Assessed until 1.5 years after the last patient enrolment</time_frame>
    <description>Time from the date of enrollment to the earlier of the date of confirmed progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>Assessed until 1.5 years after the last patient enrolment</time_frame>
    <description>Time from the date of enrollment to the earlier of the date of confirmed progression, death from any cause, or discontinuation of protocol treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Assessed at 6, 12 week and thereafter every 8 weeks</time_frame>
    <description>Proportion of eligible patients with measurable lesions with a best overall response of CR or PR assessed by the attending physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Assessed at 6, 12 week and thereafter every 8 weeks</time_frame>
    <description>Proportion of best overall response of CR, PR, or SD assessed by the attending physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Dose Intensity</measure>
    <time_frame>Assessed until final dosing to the last patient</time_frame>
    <description>will be calculated for each drug to evaluate treatment compliance in the all-treated population during the observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (Adverse Reactions)</measure>
    <time_frame>Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery</time_frame>
    <description>The incidence of worst-grade adverse events (toxicities) on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm in all treated patients for the following events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between UGT1A1 genotype and safety</measure>
    <time_frame>Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery</time_frame>
    <description>The incidence of worst-grade adverse events on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm and UGT1A1 genotype in all treated patients with a known UGT1A1 genotype profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Intestinal Neoplasms</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Digestive System Neoplasms</condition>
  <arm_group>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELIRI +/- Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPT-11 (Irinotecan)</intervention_name>
    <description>150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU Bolus</intervention_name>
    <description>400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU Infusion</intervention_name>
    <description>2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>l-LV (dl-LV)</intervention_name>
    <description>200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI +/- Bevacizumab</arm_group_label>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.</description>
    <arm_group_label>XELIRI +/- Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPT-11 (Irinotecan)</intervention_name>
    <description>150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.</description>
    <arm_group_label>XELIRI +/- Bevacizumab</arm_group_label>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.</description>
    <arm_group_label>XELIRI +/- Bevacizumab</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically-confirmed inoperable colorectal adenocarcinoma excluding vermiform&#xD;
             appendix cancer and anal canal cancer.&#xD;
&#xD;
          2. Age ≥20 years at the time of informed consent&#xD;
&#xD;
          3. ECOG performance status (PS) of 0-2&#xD;
&#xD;
          4. Written informed consent prior to study-specific screening procedures&#xD;
&#xD;
          5. Life expectancy of at least 90 days&#xD;
&#xD;
          6. Withdrawal from first-line chemotherapy (regardless of containing molecular-targeted&#xD;
             drugs) for metastatic colorectal cancer due to intolerable toxicity or progressive&#xD;
             disease, or relapse within 180 days after the last dose of adjuvant chemotherapy.&#xD;
&#xD;
          7. Adequate organ function according to following laboratory values obtained within 14&#xD;
             days before enrolment (excluding patients who received blood transfusions or&#xD;
             hematopoietic growth factors within 14 days before the laboratory test) Neutrophil&#xD;
             count: ≥1500/mm3 Platelet count: ≥10.0 x 104/mm3 Hemoglobin: ≥9.0 g/dL Total&#xD;
             bilirubin: ≤1.5 mg/dL AST, ALT: ≤100 IU/L (≤200 IU/I if liver metastases present)&#xD;
             Serum creatinine: ≤1.5 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other malignancy with a disease-free interval &lt;5 years (other than&#xD;
             curatively treated cutaneous basal cell carcinoma, curatively treated carcinoma in&#xD;
             situ of the cervix, and gastroenterological cancer confirmed to be cured by endoscopic&#xD;
             mucosal resection)&#xD;
&#xD;
          2. With massive pleural effusion or ascites requiring intervention&#xD;
&#xD;
          3. Radiological evidence of brain tumor or brain metastases&#xD;
&#xD;
          4. Active infection including hepatitis&#xD;
&#xD;
          5. Any of the following complication:&#xD;
&#xD;
             i) Gastrointestinal bleeding or gastrointestinal obstruction (including paralytic&#xD;
             ileus) ii) Symptomatic heart disease (including unstable angina, myocardial&#xD;
             infarction, and heart failure) iii) Interstitial pneumonia or pulmonary fibrosis iv)&#xD;
             Uncontrolled diabetes mellitus v) Uncontrolled diarrhea (that interferes with daily&#xD;
             activities despite adequate therapy)&#xD;
&#xD;
          6. Any of the following medical history:&#xD;
&#xD;
             Myocardial infarction: History of one episode within one year before enrollment or two&#xD;
             or more lifetime episodes i) Serious hypersensitivity to any of the study drugs ii)&#xD;
             History of adverse reaction to fluoropyrimidines suggesting dihydropyrimidine&#xD;
             dehydrogenase (DPD) deficiency&#xD;
&#xD;
          7. Previous treatment with irinotecan hydrochloride&#xD;
&#xD;
          8. Current treatment with atazanavir sulfate&#xD;
&#xD;
          9. Previous treatment with tegafur, gimeracil, and oteracil potassium within seven days&#xD;
             before enrollment&#xD;
&#xD;
         10. Pregnant or lactating females, and males and females unwilling to use contraception&#xD;
&#xD;
         11. Requires continuous treatment with systemic steroids&#xD;
&#xD;
         12. Psychiatric disability that would preclude study compliance&#xD;
&#xD;
         13. Otherwise determined by the investigator to be unsuitable for participation in the&#xD;
             study&#xD;
&#xD;
         14. Concurrent gastrointestinal perforation or history of gastrointestinal perforation&#xD;
             with 1 year before enrollment&#xD;
&#xD;
         15. History of pulmonary hemorrhage/hemoptysis ≥ Grade 2 (defined as bright red blood of&#xD;
             at least 2.5mL) within 1 month prior to enrollment.&#xD;
&#xD;
         16. History of laparotomy, thoracotomy, or intestinal resection within 28 days before&#xD;
             enrollment&#xD;
&#xD;
         17. Unhealed wound (except suture wounds from implantation of a central venous port),&#xD;
             gastrointestinal ulcer, or traumatic fracture&#xD;
&#xD;
         18. Current or recent (within 1 year) thromboembolism or cerebrovascular disease&#xD;
&#xD;
         19. Currently receiving or requires anticoagulation therapy (&gt; 325 mg/day of aspirin)&#xD;
&#xD;
         20. Bleeding diathesis, coagulopathy, or coagulation factor abnormality (INR ≥1.5 within&#xD;
             14 days before enrollment)&#xD;
&#xD;
         21. Uncontrolled hypertension&#xD;
&#xD;
         22. Urine dipstick for proteinuria &gt;+2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kei Muro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aichi Cancer Center Hospital, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Won Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASAN Medical center, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Suk Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruihua Xu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-Sen University Cancer Center, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NPO Epidemiological and Clinical Research Information Network (ECRIN)</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>January 6, 2019</last_update_submitted>
  <last_update_submitted_qc>January 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AXEPT</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>CPT-11</keyword>
  <keyword>XELIRI</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>2nd-line metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

